Bond.az - Mira Pharmaceuticals Inc (NASDAQ:MIRA) shares rose 5.1% in premarket trading Thursday after the company reported positive Phase 1 trial results for Ketamir-2, an oral NMDA receptor modulator.
The double-blind, placebo-controlled study involved 57 healthy volunteers. No serious adverse events were reported, and adverse events were more common in the placebo group.
Pharmacokinetic analysis showed rapid oral absorption and dose-proportional Cmax. The half-life of Ketamir-2 ranged from 2.5 to 7 hours.
Mira is preparing to submit its Phase 2a protocol to the FDA, targeting chemotherapy-induced peripheral neuropathy, a condition with no approved therapies.
The global market for this condition is projected to reach $1.7 billion by 2035.
